Study of AK120 for teens with moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new drug called AK120 for adolescents aged 12 to under 18 with moderate-to-severe atopic dermatitis (eczema). It aims to see if AK120 can improve skin symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 to under 18 years old.
- You must weigh at least 66 pounds (30 kg).
- You must have had eczema for at least 6 months.
- Your eczema must cover at least 10% of your body and be moderate to severe (assessed by a doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called AK120, given as an injection, to see if it helps teenagers with moderate-to-severe eczema (also called atopic dermatitis) that is not well controlled. It may be a good option for teens who need stronger treatment.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.